LiPyDau: a promising novel agent for drug resistant cancers?
Researchers have developed a potent chemotherapeutic agent, LiPyDau, for drug-resistant cancers.
Promising pre-clinical results have outlined how researchers from have achieved the safe delivery of a highly toxic type of chemotherapy using an encapsulation method. The research, published recently in the journal Molecular Science (Spinger Nature), could open new treatment avenues for tumors that are drug resistant.
In clinical settings, chemotherapies such as anthracyclines prevail as the cornerstone of cancer treatment. However, anthracyclines are often hindered by drug resistance, severe cardiotoxicity and drug efflux mechanisms.
A research team, led by Gergely Szakács (Medical University of Vienna), sought to overcome this by developing a safe way of developing a known highly potent chemotherapeutic agent with reduced side effects.
The new compound, 2-pyrrolino-daunomycin (PyDau), a daunorubicin analog, was previously unsuitable for in vivo use due to its high toxicity. To overcome this, the team of researchers encapsulated it within liposomes, resulting in the formulation LiPyDua.
Positive efficacy tests of LiPyDua were observed in aggressive tumour models such as genetically engineered BRCA1-deficient breast cancer mouse models and patient-derived xenografts of lung adenocarcinoma. It has also shown to overcome P-glycoprotein-mediated drug resistance, a major limitation of conventional liposomal anthracyclines.
Study leader Gergely Szakács stated: “Our studies in mouse models show that encapsulating 2-pyrrolino-daunorubicin in liposomes enables the safe use of an otherwise too toxic, yet extremely potent new drug. The next important step is to conduct further studies to determine whether these promising results can be translated into clinical applications.”
Although this represents a significant advancement in liposomal drug delivery and cancer therapy, further clinical development and human trials are required to establish the safety and efficacy of LiPyDau.